New Data Supports Potential Role of AI in Predicting Patient Response to Immunotherapies
13 November 2023
Collaborations, Mergers & Acquisitions
GE HealthCare has announced new data that validates Artificial Intelligence models for predicting patient response to immunotherapies. AI models demonstrated a significant percentage of accuracy enabling clinics to match patients to the most effective treatment sooner.
With roughly 5,000 immunotherapies in development today, selecting patients who are more likely to respond to treatment could potentially help drug developers accelerate the drug development process and increase the likelihood of success of clinical trials. Immunotherapies are often more effective with fewer side effects; however, response rates remain low and can be severe.
To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data.
“Immunotherapy can offer significant benefits for patients but given the current unpredictability of some reactions to treatment, it can also be associated with increased morbidity and cost,” commented Travis Osterman, DO, MS, Associate Vice President for Research Informatics and Associate Chief Medical Information Officer for Vanderbilt University Medical Center, and Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center.
“These results pave the way for the ability to better select which patients should benefit and which would be better suited to an alternative form of treatment,” continued Osterman.
GE Healthcare’s Pharmaceutical Diagnostics division is a world leader in imaging agents that aid in approximately 100 million procedures annually, which is equivalent to three patient procedures every second on a global scale.
“We are keen to partner with pharmaceutical companies, researchers, and clinicians to optimize and apply our AI models in therapy development and in clinical practice in a longer term,” said Julia Casey, General Manager Molecular Imaging at GE HealthCare’s Pharmaceutical Diagnostics segment.
The Molecular Imaging portfolio comprises established proprietary products in cardiology, neurology, and oncology, along with a cutting-edge pipeline aimed at providing better-informed diagnosis and monitoring for enhanced therapy decision-making and clinical outcomes.
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.